Reference/Dual GLP-1/GIP agonist

Tirzepatide

Dual GIP/GLP-1 Receptor Agonist · Weight Loss & Diabetes

Human preliminary

research use only

Revolutionary dual receptor agonist FDA-approved for type 2 diabetes and chronic weight management. Demonstrates efficacy superior to single-mechanism alternatives with 15-22% body weight reduction in clinical trials. The first-in-class dual GIP/GLP-1 agonist provides enhanced metabolic benefits compared to GLP-1-only medications.

Dramatic weight loss (15-22% body weight)Superior diabetes controlReduced cardiovascular risk (26% reduction in MACE)Improved insulin sensitivity

8 citations·1 with human data·Updated 10 Aug 2026

Overview

Dual agonist targeting both GIP and GLP-1 receptors, producing glucose-dependent insulin stimulation, delayed gastric emptying, glucagon suppression, and central satiety signaling via hypothalamic pathways.

Evidence profilederived from 8 references

Human preliminary

Strongest design among the references on this page. Grade and effect size are separate facts and are never merged into one score.

Research indications

What the compound has been studied for, grouped by body system. Effect size is the reported magnitude where it was measured — not a recommendation.

Weight Loss3

Severe Obesity Management

Clinical trials demonstrate 15-22% body weight reduction in non-diabetic obese individuals, superior to existing weight loss medications.

Large

Metabolic Syndrome Reversal

Improvements in waist circumference, blood pressure, triglycerides, HDL cholesterol, and insulin resistance markers.

Large

Body Composition Optimization

Preferentially reduces visceral adipose tissue while preserving lean muscle mass with resistance training.

Moderate

Diabetes3

Type 2 Diabetes Management

Superior HbA1c reduction of 1.5-2.4% in clinical trials.

Large

Insulin Resistance Improvement

Improves insulin sensitivity across diverse populations.

Moderate

Beta Cell Preservation

May help preserve and restore pancreatic beta cell function.

Moderate

Cardiovascular3

MACE Reduction

26% reduction in major adverse cardiovascular events demonstrated in SURPASS-CVOT trial.

Moderate

Blood Pressure Reduction

Systolic and diastolic blood pressure reductions of 8-12 mmHg.

Moderate

Lipid Profile Improvement

Triglyceride improvements of 20-30%, HDL enhancement, and apolipoprotein B reduction.

Small

A large effect in a weak study and a small effect in a strong one are different things. Effect size is never evidence of use in people.

Quick factsreference only

Class: Dual GLP-1/GIP agonist
Chain length: 39 residues
Molecular weight: 4813.55 Da
Half-life: ~120 h
Typical dose: 2.5mg starting, titrate up to 5-15mg weekly
Frequency: Once weekly (same day each week)
Cycle length: Ongoing therapy as prescribed
Storage: Pen: 2-8°C before first use, room temp up to 21 days after. Compounded: 2-8°C

Molecular data

Type: Dual GLP-1/GIP agonist
Molecular weight: 4813.55 Da
Chain length: 39 residues
Half-life: 7200 min

Dosing reference

Doses reported in the literature and by suppliers. These are a record of what has been used in research — reference, never instruction.

Context	Route	Amount	Frequency
Weight loss initiation	SubQ injection	2.5mg	Once weekly x 4 weeks
Weight loss progression	SubQ injection	5mg	Once weekly
Weight loss optimization	SubQ injection	7.5-10mg	Once weekly
Maximum weight loss	SubQ injection	12.5-15mg	Once weekly
Diabetes management (mild)	SubQ injection	5-7.5mg	Once weekly
Diabetes management (severe)	SubQ injection	10-15mg	Once weekly

Interactions

Semaglutide

Both are GLP-1 agonists—combining increases hypoglycemia and severe GI side effect risk.

avoid

Liraglutide

Another GLP-1 agonist—dual therapy contraindicated due to additive effects.

avoid

Insulin

May require significant insulin dose reduction due to improved sensitivity.

monitor

Metformin

Complementary mechanisms for diabetes management and weight loss.

synergistic

CJC-1295

Growth hormone support may help preserve muscle mass during weight loss.

compatible

Ipamorelin

May help maintain metabolic rate and muscle preservation.

compatible

BPC-157

No known interactions, may support gut health and reduce GI effects.

compatible

5-Amino-1MQ

NNMT inhibition may complement GLP-1 effects for metabolic optimization.

compatible

Quality checklist

✓White to off-white lyophilized powder without clumping
✓Clear, colorless reconstituted solution
✓Intact vial seal with visible mg dosage labeling and batch numbers
✓Proper storage maintenance at 2-8°C, protected from light
!Compounded versions without proper quality control
×Powder clumping, discoloration, or yellow/brown appearance
×Persistent cloudiness after reconstitution
×Unusual crystallization patterns

What to expect

Day 1-3Appetite reduction begins

Week 1-2Improved blood sugar control (diabetics), mild nausea common

Week 2-4Initial weight loss begins; GI side effects typically improve

Ongoing1-3 lbs weight loss per week during active phase

Week 16-24Peak weight loss effects observed

Safety

Commonly reported5

Nausea (mild to moderate, first 2-4 weeks)
Appetite reduction
Possible fatigue during adaptation
Diarrhea or constipation
Reduced food cravings

Stop and seek advice9

Severe/persistent abdominal pain (pancreatitis risk)
Neck lumps, hoarseness, difficulty swallowing (thyroid concerns)
Severe nausea/vomiting preventing adequate nutrition
Severe hypoglycemic signs (confusion, sweating, rapid heartbeat)
Kidney problems (decreased urination, swelling)
Severe allergic reactions (rash, breathing difficulty)
Suicidal thoughts or severe depression
Gallbladder problems (severe upper right pain)
Dehydration from persistent vomiting

Contraindications4

Personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Pregnancy or breastfeeding
History of pancreatitis

FAQ

How much weight does tirzepatide cause compared to semaglutide?

Tirzepatide achieves 20.2% weight loss vs semaglutide's 13.7% at 72 weeks in head-to-head trials (SURMOUNT-5). The dual GIP/GLP-1 mechanism makes tirzepatide significantly more effective - nearly 7% greater weight reduction, with 57% of tirzepatide users achieving ≥20% weight loss.

Can tirzepatide improve heart failure with preserved ejection fraction (HFpEF)?

Yes, the SUMMIT trial showed tirzepatide reduced the composite of cardiovascular death or worsening heart failure by 38% in HFpEF patients with obesity. This represents a major cardiovascular indication beyond weight loss and diabetes, establishing tirzepatide as cardioprotective at the tissue level.

Does tirzepatide help prevent progression from prediabetes to diabetes?

Yes, 3-year data from SURMOUNT-1 extension showed a 93% reduction in progression to type 2 diabetes in prediabetic individuals with obesity treated with tirzepatide. Combined with sustained 19.7% weight loss, this makes it highly effective for diabetes prevention in at-risk populations.

Why would someone choose tirzepatide over a lower-cost GLP-1 like semaglutide?

Superior weight loss efficacy (20% vs 13%), cardiovascular outcome benefits (38% HFpEF improvement), and once-weekly convenience make tirzepatide worth higher cost for patients seeking maximal results. The SURPASS and SUMMIT trials show tirzepatide superiority justifies premium pricing for optimized outcomes.

References

1
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)
Frías, J.P., et al. · New England Journal of Medicine · 2021
Tirzepatide was noninferior and superior to semaglutide 1mg for HbA1c reduction and weight loss in type 2 diabetes. The 15mg dose achieved nearly twice the weight loss of semaglutide.
human-pilotPubMed 34170647 ↗
2
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
Jastreboff, A.M., et al. · New England Journal of Medicine · 2022
Landmark phase 3 trial: 15mg weekly achieved 22.5% weight loss vs 2.4% placebo over 72 weeks. Weight reduction of ≥20% achieved in 57% of 15mg recipients.
reviewPubMed 35658024 ↗
3
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)
Garvey, W.T., et al. · The Lancet · 2023
15mg dose achieved 15.7% weight loss over 72 weeks with significant cardiometabolic improvements. 79-83% of tirzepatide recipients achieved ≥5% weight loss vs 32% placebo.
reviewPubMed 37385275 ↗
4
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT)
Packer, M., et al. · New England Journal of Medicine · 2024
Tirzepatide reduced the composite of CV death or worsening heart failure by 38% (HR 0.62) vs placebo over median 104 weeks. Improved health status scores and 6-minute walk distance.
reviewPubMed 39555826 ↗
5
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA)
Malhotra, A., et al. · New England Journal of Medicine · 2024
Tirzepatide significantly reduced AHI with resolution of OSA in approximately 50% of participants. Also reduced body weight, hypoxic burden, hsCRP, and systolic blood pressure.
reviewPubMed 38912654 ↗
6
Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 3-Year Extension)
Jastreboff, A.M., et al. · New England Journal of Medicine · 2025
Three years of tirzepatide resulted in sustained weight reduction of up to 19.7% (15mg) and 93% lower risk of progression to type 2 diabetes vs placebo (HR 0.07).
reviewPubMed 39536238 ↗
7
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5)
Aronne, L.J., et al. · New England Journal of Medicine · 2025
Head-to-head comparison: tirzepatide achieved 20.2% weight loss vs 13.7% with semaglutide at 72 weeks. Tirzepatide was superior for body weight and waist circumference reduction.
reviewPubMed 40353578 ↗
8
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (SURPASS-CVOT)
Nicholls, S.J., et al. · New England Journal of Medicine · 2025
Tirzepatide was noninferior to dulaglutide for MACE (composite of CV death, MI, or stroke). Several secondary endpoints favored tirzepatide, including reduced all-cause mortality after 4-year median follow-up.
reviewPubMed 41406444 ↗